vTv Therapeutics: Late-Stage Cadisegliatin Data, Differentiated Mechanism, and Partnered T2D Expansion Underpin Buy Rating and $40 Target

Analyst Kambiz Yazdi of BTIG maintained a Buy rating on vTv Therapeutics, retaining the price target of $40.00.

Kambiz Yazdi has given his Buy rating due to a combination of factors tied to the strength of vTv Therapeutics’ lead asset, cadisegliatin, and its late-stage development in type 1 diabetes. He expects the ongoing Phase 3 CATT1 trial, which targets a meaningful reduction in serious hypoglycemic episodes versus insulin alone and adheres to current FDA guidance, to read out in the second half of 2026 and views the design as robust. His confidence is grounded in earlier clinical results from the SimpliciT1 Phase 2 program, where cadisegliatin lowered HbA1c and substantially reduced hypoglycemia without increasing ketoacidosis, and in a separate insulin-withdrawal study suggesting potential protective effects against diabetic ketoacidosis. He also highlights cadisegliatin’s favorable safety profile and its liver-selective glucokinase activation mechanism, which supports improved glucose storage and release and provides a clear biological rationale for reducing hypoglycemia.
In addition, Yazdi points to vTv’s efforts to broaden cadisegliatin’s commercial and clinical footprint through a Phase 2 type 2 diabetes trial in collaboration with M42, which will be fully funded by the partner and expand the drug’s geographic reach into the UAE and other regions. This strategy not only diversifies the development pathway across T1D and T2D, but also targets areas with high diabetes prevalence, potentially enhancing future market opportunities. Finally, his bullish stance is reinforced by a valuation framework that yields a $40 price target, derived primarily from a long-dated discounted cash flow analysis supplemented by a peak sales multiple, suggesting substantial upside from current levels. Taken together, the late-stage catalyst, strong prior efficacy and safety data, differentiated mechanism, partnership leverage, and attractive risk‑reward profile support his Buy recommendation on VTVT.

In another report released on January 5, TD Cowen also initiated coverage with a Buy rating on the stock with a $67.00 price target.